New Olympus Ultra-Portable EPOCH® 6LT Flaw Detector Provides Comprehensive Flaw Detection Capabilities for Rope Access and High Portability Inspections
27.6.2017 12:30 | Business Wire
Optimized for single-handed operation, the EPOCH 6LT flaw detector combines a leading-edge ergonomic design with powerful ultrasonic functionality in an instrument built specifically for rope access and high portability applications.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170627005058/en/
The design of the EPOCH 6LT flaw detector, from form factor to the user interface, is optimized for user comfort, making it easy to use with one hand, so rope access inspection technicians and users that require high portability can do their work comfortably and efficiently.
- Fits securely in one hand with minimal wrist fatigue: weighs just 1.95 lbs (890 g) with a grip-oriented weight distribution
- Attaches to a user’s leg or harness: rope access technicians can secure the instrument for hands-free operation
- Users can navigate the menu using just their thumb: the rotary knob and simple button design make it easy to navigate through the UI, even while wearing gloves
- Durable and reliable: engineered to IP65/67 for dust and water resistance and drop tested to protect against the hazards found in challenging inspection environments
The EPOCH 6LT flaw detector’s workflow is simple and straightforward so technicians can spend more time on their inspection and less time adjusting the instrument. Despite the instrument’s small size, it has the features and functions to meet the requirements of nearly any conventional ultrasonic inspection application, including all the core functionality of the popular EPOCH 650 flaw detector and EN12668-1:2010 compliance.
- Intuitive software: a two-screen, icon-based interface makes navigation quick and easy
- Efficient inspections: the hardware and software maximize one-handed operation, so users can use their other hand to maneuver the probe
- Optional corrosion software: combine the ease of use of a thickness gage with the flexibility of a flaw detector; with center-pin transducer ID for faster set up
- Optional Wi-Fi connectivity: take advantage of on-the-go data backups, setup downloads, and powerful cloud applications on the Olympus Scientific Cloud
For rope access technicians, the EPOCH 6LT flaw detector offers features to help keep them safe during challenging inspections. For added efficiency, users can control the inspection parameters with one hand without interrupting flaw scanning. With the rope access accessory kit, technicians can secure the instrument to their leg or harness, leaving both hands free to maintain balance or adjust the probe. Depending on how the instrument is attached, the display rotates so users can properly view the A-scan and readings.
Olympus Corporation operates in industrial, medical, and consumer markets, specializing in optics, electronics, and precision engineering. Olympus is a world-leading manufacturer of innovative test and measurement solutions that are used in industrial and research applications ranging from aerospace, power generation, petrochemical, civil infrastructure, and automotive to consumer products.
For more information about the EPOCH 6LT flaw detector and Olympus’ full line of nondestructive testing products contact a sales representative or visit www.olympus-ims.com.
EPOCH is a registered trademark of Olympus Corporation.
Calvin Jory, 781-419-3549
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
XILAM Successfully Completes €15m Bond Issue on Euro PP Market27.7.2017 17:42 | Pressemelding
Regulatory News: Xilam (Paris:XIL) today announced the completion of its Euro PP bond issue. The €15 million private placement, repayable at maturity, was subscribed by the NOVI 2 fund managed by Idinvest Partners on behalf of institutional investors and by a European insurer. The bonds have a 6-year maturity, and will be issued in two tranches: The first tranche will be at a variable rate of 6-month EURIBOR* + 400 bp The second tranche will be at a fixed rate of 3.5%. Favourable terms were obtained for the issue with successive drawdown options (limited to 18 months), which will allow the company to optimise the cost of its debt according to its needs. Xilam was advised on the transaction by Euroland Corporate. “We are delighted to have successfully completed this financing transacti
SFL – First-Half 2017 Results27.7.2017 17:00 | Pressemelding
Regulatory News: The interim consolidated financial statements for the six months ended 30 June 2017 were approved by the Board of Directors of Société Foncière Lyonnaise (Paris:FLY) on 27 July 2017, at a meeting chaired by Juan-Jose Brugera. First-half business indicators were robust, thanks to the high portfolio occupancy rate, while the period also saw gains in the portfolio's appraisal value and the Company's net asset value. The auditors have completed their review of the interim financial statements. Consolidated data (€ millions)
Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 13:00 | Pressemelding
Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of
Acxiom Launches Connected Spaces27.7.2017 12:30 | Pressemelding
Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative
Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 12:08 | Pressemelding
On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to
European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 11:05 | Pressemelding
Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom